FDA Flags Non-Compliance at Novo Nordisk’s Indiana Plant Impacting Biotech Drug Production

The FDA has identified compliance issues at Novo Nordisk’s manufacturing facility in Indiana, which is crucial for producing drugs for various biotech companies. This non-compliance status may cause delays in the approval process for medications manufactured at the site.